âAfter more than a decade of joint respiratory research and development, the approval is a very important milestone for Theravance and GSK.â. Following this approval by the FDA, it is anticipated that BREO ELLIPTA will be available in the US during the third quarter of 2013. Under the terms of the 2002 LABA collaboration agreement, Theravance is obligated to make a milestone payment of $30 million (USD) to GSK following FDA approval of BREO ELLIPTA.
More on The Christian Science Monitor. The Christian Science Monitor is an independent international news organization with the stated goal of understanding the worldâs problems in order to move toward solutions. Mary Baker Eddy, the founder of Church of Christ, Scientist, founded the Christian Science Monitor in 1908.
CAP Accreditation, CLIA Certifications and State Licenses. The HudsonAlpha Clinical Services Lab (CSL) offers personalized genomic testing for the identification of rare and undiagnosed disease. The sequencing and interpretation pipeline is accredited by the College of American Pathologists (CAP) and certified through Clinical Laboratory Improvement Amendments (CLIA).